Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934878 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL10567265 | 0.93 | ALDH1A1 (0.47) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL29785367 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL12491675 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL1766175 | 0.85 | ALDH1A1 (0.58) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL31377991 | 0.85 | ALDH1A1 (0.58) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL4103425 | 0.84 | MAPT (0.49) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL30230904 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL30801468 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL4279356 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TDP1MAPTKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820120-A | Method for preparing 4-nitro-2-bromo-5-fluoroanisole through continuous flow diazotization reaction | 浙江晖石药业有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| WO-2025049555-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025037871-A1 | TRICYCLIC COMPOUND AND USE THEREOF AS MAT2A INHIBITOR | 에스케이바이오팜 주식회사 | 2025-02-20 | — | — | WO | disclosed |
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20140031351-A1 | Macrocyclic Compounds as ALK, FAK and JAK2 Inhibitors | CEPHALON, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2686323-A1 | MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-1939204-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | disclosed |
| CN-101331134-B | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL | 2012-11-28 | — | — | CN | disclosed |
| WO-2012125603-A1 | MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101331134-A | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL (JP) | 2008-12-24 | — | — | CN | disclosed |
| EP-1939204-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | ALDH1A1 3236/4885TDP1 3050/4885MAPT 2234/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ALDH1A1 3316/4885TDP1 1684/4885MAPT 2462/4885 |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | SHBG, CYP19A1, NR5A1 | ALDH1A1 1048/4885TDP1 4552/4885MAPT 4837/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ALDH1A1 3316/4885TDP1 1684/4885MAPT 2462/4885 |
| US-20140031351-A1 | Macrocyclic Compounds as ALK, FAK and JAK2 Inhibitors | JAK2, ALK, JAK1 | ALDH1A1 1755/4885TDP1 2838/4885MAPT 4256/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | ALDH1A1 3713/4885TDP1 3232/4885MAPT 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.